Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Phibro Animal Health's Revenue for the
three
months ended in Mar. 2026 was $384 Mil. Phibro Animal Health's average Accounts Receivable for the
three
months ended in Mar. 2026 was $219 Mil.
Hence, Phibro Animal Health's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.75.
Phibro Animal Health (NAS:PAHC) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Phibro Animal Health Receivables Turnover Related Terms
Phibro Animal Health Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Phibro Animal Health's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PAHC vs PRGO, HROW, XERS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Phibro Animal Health's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phibro Animal Health Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Phibro Animal Health's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Phibro Animal Health's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phibro Animal Health (PAHC) has a Receivables Turnover of 1.75 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Phibro Animal Health and its competitors. According to the industry distribution chart, Phibro Animal Health ranks #265 out of 950 companies in the Drug Manufacturers industry, placing it in the top 27.9%.
Is Phibro Animal Health's Receivables Turnover too high?
Phibro Animal Health's current Receivables Turnover is 1.75. The Drug Manufacturers industry median Receivables Turnover is 5.06. Phibro Animal Health's value of 1.75 is 65.4% below this industry median. Based on the distribution chart, Phibro Animal Health ranks #265 out of 950 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Phibro Animal Health has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Phibro Animal Health's Receivables Turnover compare to PRGO and HROW?
According to the Drug Manufacturers industry distribution chart, Phibro Animal Health ranks #265 out of 950 companies for Receivables Turnover. This puts Phibro Animal Health in the upper half of its industry. The industry median Receivables Turnover is 5.06. Phibro Animal Health's value of 1.75 is 65.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.06, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phibro Animal Health's current Receivables Turnover of 1.75 is 65.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Phibro Animal Health and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phibro Animal Health's current Receivables Turnover is 1.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phibro Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Phibro Animal Health (PAHC) is currently considered Modestly Overvalued. The stock's GF Value™ is $29.54, compared to a current price of $34.26 — trading 16% above its estimated fair value. The current Receivables Turnover is 1.75 and 65.4% below the Drug Manufacturers industry median of 5.06. Phibro Animal Health's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Phibro Animal Health (PAHC), the current Receivables Turnover is 1.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Phibro Animal Health (PAHC) Overvalued in 2026?
Based on GuruFocus' analysis, Phibro Animal Health stock appears to be overvalued.
The current stock price of $34.26 is trading 16% above its estimated GF Value™ of $29.54.
GuruFocus considers Phibro Animal Health to be Modestly Overvalued.
Key valuation signals for PAHC:
Receivables Turnover: 1.75
GF Value™: $29.54 vs. price of $34.26 (16% above fair value)
Industry Position: 65.4% below the Drug Manufacturers median (#265 of 950)
No single metric tells the full story. See the PAHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
75GF Score
Get the complete analysis for PAHC
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PAHC has been successfully added to your 
